Abstract Major depressive disorder (MDD) is a significant cause of morbidity and mortality worldwide, correlating with genetic susceptibility and environmental risk factors. Molecular, functional, and structural imaging approaches have been increasingly used to detect neurobiological changes, analyze neurochemical correlates, and parse pathophysiological mechanisms underlying MDD. We reviewed recent neuroimaging publications on MDD in terms of molecular, functional, and structural alterations as detected mainly by magnetic resonance imaging (MRI) and positron emission tomography. Altered structure and function of brain regions involved in the cognitive control of affective state have been demonstrated. An abnormal default mode network, as revealed by resting-state functional MRI, is likely associated with aberrant metabolic and serotonergic function revealed by radionuclide imaging. Further multi-modal investigations are essential to clarify the characteristics of the cortical network and serotonergic system associated with behavioral and genetic variations in MDD.
Introduction
Major depressive disorder (MDD) is one of the most common and costly mental disorders, with a lifetime prevalence of [16% [1] and an annual financial burden of [200 billion dollars in the USA [2] . According to the latest report, MDD has been ranked as the second medical condition with the greatest disease burden worldwide based on years lived with disability [3] . MDD is associated with numerous negative consequences, including health and social issues, among which suicide is the most devastating consequence attempted by as many as 8% of severe MDD patients [4] . Strikingly, only *50% of MDD patients respond to standard-of-care antidepressants [5] , with *70% failing to achieve complete remission [6] . Thus, it is necessary to understand the potential mechanisms in order to explore more effective diagnostic and therapeutic strategies for MDD.
Over the past several decades, molecular, functional, and structural imaging approaches such as single photon emission computed tomography (SPECT), positron emission tomography (PET), and magnetic resonance imaging (MRI), have been increasingly applied to elucidate the neurobiological mechanisms underlying MDD. Molecular imaging is defined as the noninvasive, real-time visualization of biological processes at the cellular and molecular levels in vivo [7, 8] . SPECT and PET provide information on disease-specific molecular changes in the brain of MDD patients [9] , and MRI provides information on brain structure, function and connectivity by using techniques of structural MRI and functional MRI (fMRI).
In this article, we present a selective review of molecular, functional and structural neuroimaging studies published since 2010. We describe the statistics from neuroimaging articles on MDD in the last 10 years, followed by a review of the reports using each neuroimaging modality, particularly structural MRI, resting-state fMRI, and metabolic and neurotransmitter PET and SPECT. Due to space limitations, we do not review papers that measured cerebral blood flow and task-related fMRI in MDD.
Statistics from Recent Neuroimaging Articles on MDD
To capture the trend of recent neuroimaging articles in MDD, we searched the PubMed database and made a publication area chart with the publication date ranging from Jan. 1, 2010 to Dec. 26, 2015 . The PubMed database was searched using the retrieving field [Title/Abstract] for neuroimaging articles on MDD and the results were classified into multiple groups based on the type of neuroimaging technique, such as MRI, PET and SPECT, and multi-modal imaging (Fig. 1) .
The search criteria were as follows. With regard to publications on MRI, the following search-string was chosen: (major depressive disorder OR major depression OR unipolar depression) AND (magnetic resonance imaging OR MRI); for publications on structural MRI, we added (structural OR structure) to the search-string of publications on MRI; for publications on fMRI, we added (function OR functional) to the search-string of publications on MRI; for resting-state fMRI and task fMRI, we added (rest OR resting) and (task OR tasking), respectively, while for publications on multi-modal fMRI, we added both (rest OR resting) and (task OR tasking). For publications on SPECT or PET, the search-string was as follows: (major depressive disorder OR major depression OR unipolar depression) AND (positron emission tomography OR single photon emission computed tomography OR radionuclide imaging OR PET OR SPECT); for publications on the aberrant serotonergic system in radionuclide imaging, we added (5-HT OR serotonin) to the search string of publications on PET or SPECT; for publications on multi-modal imaging with PET and MRI, we used (major depressive disorder OR major depression OR unipolar depression) AND (magnetic resonance imaging OR MRI) AND (positron emission tomography OR single photon emission computed tomography OR radionuclide imaging OR PET OR SPECT), and selected each paper using multi-modal imaging approaches in its methods by looking though its abstract.
The results of the PubMed search showed that the number of neuroimaging articles on MDD has increased rapidly in the past decade (Fig. 1a) . In particular, the number of MRI studies in 2015 was double that in 2010 (*100 versus *50), while the number of PET and SPECT Fig. 1 The publication trend of neuroimaging articles using PET, MRI, and/or multi-modal imaging approaches in MDD from 2006 to 2015. a Publication trend of articles using PET/SPECT, MRI and multi-modal imaging with PET/SPECT and MRI. b Publication trend of studies investigating functional and structural alterations using various MRI approaches. c Publication trend of articles using PET or SPECT in investigating serotonergic system or others studies remained relatively stable. With regard to the details of MRI studies (Fig. 1b) , structural MRI and resting-state MRI are becoming the major imaging methods. While the numbers of structural MRI and task fMRI studies are gradually increasing, the number of resting-state fMRI studies is increasing rapidly. In addition, the numbers of studies exploiting multiple (multi-modal) MRI techniques for understanding MDD have also increased. Among PET or SPECT studies, articles on serotonergic dysfunction seem to occupy the major part (Fig. 1c) . Based on these statistics, we focused on reviewing articles using structural MRI, resting-state fMRI and PET or SPECT published since 2010.
MRI
MRI has the ability to characterize a wide range of imaging contrasts in living tissues, and visualizes tissue morphology and function in vivo with the use of magnetic field and radiofrequency [10] . The predominant superiority of MRI as a molecular imaging modality is its high spatial resolution (micrometers). Thus, morphological study of the brain has been a major interest in the field of MRI studies of MDD. Imaging techniques for morphological MRI include not only conventional structural MRI for evaluating regional gray matter volume but also the recent method of diffusion tensor MRI that captures microstructural changes in white matter. In addition, fMRI has emerged as a noninvasive approach that enables the monitoring neural activity changes based on the blood-oxygen-level-dependent signal [11] . In particular, resting-state fMRI is easy to perform and does not require any task performance. Structural MRI and resting-state fMRI are the major MRI modalities (Fig. 1b) .
MR Imaging of Brain Morphology and Structure
A number of structural MRI studies of MDD have shown morphological abnormalities, mainly cortical thickness, gray matter volume, and white matter integrity [12] [13] [14] [15] [16] [17] , particularly in the frontal areas.
Voxel-based morphometry (VBM) is a powerful and objective approach that allows whole-brain assessment of anatomical abnormalities (for methodology, see [18] ). Due to its simplicity of use, VBM has motivated many neuroscientists to characterize the specific abnormalities of graymatter volume throughout the brain in MDD [15, 19, 20] . Recent meta-analysis of VBM in MDD has shown strong evidence of gray-matter volume reduction in the anterior cingulate cortex (ACC) [21] [22] [23] . The ACC is involved in multiple cognitive and affective functions, such as decision-making [24] , empathy [25] , conflict-monitoring [26] , working memory, attention, and informationprocessing [27] . Thus, structural alterations in the ACC may be associated with the affective and cognitive dysfunctions in MDD. Some studies have focused on the early morphological changes in first-episode, medication-naive MDD patients [28] [29] [30] . A recent study in untreated, firstepisode, mid-life MDD patients showed a modestly negative correlation between cortical thickness in the rostral middle frontal cortex and depression severity based on the Hamilton Depression Rating Scale (HDRS) [31] (Fig. 2) , indicating that increased thickness might be present in milder cases or that it might represent a compensation for inflammatory factors or other aspects of the pathophysiology of MDD. Similarly, a recent, prospective, longitudinal study demonstrated that a thicker right caudal ACC at baseline is associated with greater symptom improvement over follow-up [32] . Besides, it has been reported that cortical thickness changes in the opposite direction over follow-up in MDD patients. Specifically, remitters showed increased while non-remitters showed decreased cortical thickness in several regions, indicating that structural recovery might occur only if patients respond to treatment. Interestingly, among the entire sample who received pharmacotherapy, only remitters showed increased hippocampal volume and cortical thickness in the rostral middle frontal gyrus, orbitofrontal cortex, and inferior temporal gyrus, whereas a previous study documented increased orbitofrontal cortical thickness in both remitters and non-remitters after antidepressant treatment [33] . Thus, it has been suggested that the reversible alterations in some frontal regions might be associated with remission itself or with antidepressant effects. The antidepressant-induced structural changes may be attributable to increased neuronal turnover, enhanced axonal and dendritic sprouting, synaptogenesis, increased numbers of glial cells, and a larger neuropil volume stimulated by antidepressants [32, 34] . But these conclusions need to be clarified in future studies.
Other VBM studies have also found structural abnormalities in regions including the insula, thalamus, and hippocampus in MDD patients [28, [35] [36] [37] [38] [39] [40] [41] [42] [43] . The anterior insula connects to the inferior frontal cortex and to the ACC [44] . It is thought to be involved in social-emotional and cognitive networks [45] , and thus may play a crucial role in the neurobiology of MDD [42] . Similarly, given that the thalamus is connected to the cortex and to negative emotion-generating limbic structures such as the amygdala [38] , the anomalous thalamic structure may account for deficits in the top-down regulation of negative affect in individuals with MDD. Moreover, the hippocampus is involved in memory function [46, 47] . MDD patients have a reduced hippocampal volume specific to the cornu ammonis and dentate gyrus subfields [35] ; this is probably due to stress-related or/and repeated neurotoxic processes associated with cumulative exposure to stress and depressive symptomatology [36, 37, 42] .
It is critical to note that, in addition to gray-matter changes, altered white-matter integrity has also been reported in MDD using diffusion tensor imaging (DTI). DTI is a unique MRI approach that allows for noninvasive detection of the orientation and integrity of white-matter tracts in vivo by evaluating the diffusion of water molecules in neural tissue (for methodology, see [48] ). One study reported reduced white-matter integrity, as measured by fractional anisotropy (FA), in the prefrontal white matter of MDD patients [49] . Another study reported decreased white-matter integrity in the right solitary fasciculus-a ''bottom up'' afferent pathway connecting the brainstem to the amygdala; this supports the hypothesis that brainstem-amygdala disconnection might be a potential mechanism of MDD [50] . Decreased white-matter integrity has also been identified in the corpus callosum, inferior fronto-occipital fasciculus, and left superior longitudinal fasciculus in MDD patients with melancholic and atypical features [51] . Intriguingly, one study showed that the FA value for anterior cingulate-limbic white matter is a predictor of the antidepressant treatment effect in MDD, i.e., patients with a higher FA in in the cingulate and a lower FA in the stria terminalis are more likely to achieve remission [52] .
Taken together, structural MRI studies using VBM and DTI have shown alterations in cortical thickness, graymatter volume, and white-matter integrity in frontal and fronto-subcortical areas in MDD patients, which may explain some of the executive, behavioral, and emotional deficits. Furthermore, several specific abnormalities in certain areas, such as cortical thickness in the rostral middle frontal cortex and right caudal ACC, and whitematter integrity in the anterior cingulate-limbic system, may be applied to predict status severity, symptom improvement, and treatment effect.
MR Imaging of Resting-State Functional Connectivity
The last six years have witnessed a rapid increase in the number of resting-state fMRI studies on functional connectivity. Increased interest in this field has emerged from the hypothesis that the intrinsic and spontaneous activity is the essence of 'default-mode' brain function [53] . Advanced methods for analyzing functional connectivity using MRI (for review, see [54] ), such as seed-based correlation analysis, independent component analysis, regional homogeneity, and amplitude of low-frequency fluctuations, have been increasingly used. Through these techniques, aberrant functional connectivity has been identified in MDD, such as in the salience network (SN) [55, 56] , default mode network (DMN) [57] [58] [59] [60] , cognitive control network (CCN) [59, 61] , and affective network (AN) [60, 62] . The SN, predominantly consisting of the anterior insular cortex and dorsal ACC, serves to assess the correlation of internal and external stimuli to produce appropriate responses and direct behaviors [63] . Dysfunction of this network might account for the negative interpretation bias common in MDD [64] . The DMN, consisting of the posterior cingulate cortex and medial prefrontal cortex (PFC) as its core areas [65, 66] and the precuneus and temporo-parietal cortices, underlies the psychological process of introspection-the mind turning internally as it moves away from externally-concentrated thoughts [67] [68] [69] . A majority of studies have demonstrated that the DMN is hyperactive in MDD [70, 71] , and this may account for the rumination states in MDD [72] . The CCN, consisting of the dorsolateral PFC and pregenual ACC [73, 74] , is thought to be involved in the top-down modulation of attention and the regulation of emotional responses [75, 76] . Dysfunction of this network may explain the attention deficits and anhedonia in MDD. The AN, consisting of the amygdala and the subgenual and pregenual cingulate, has been implicated in appetite, libido, and sleep, so hyperactivity of this network may explain the vegetative disturbances in MDD patients [71] .
Using resting-state fMRI, one study investigated the DMN, CNN, and AN simultaneously [71] , and showed that all three networks had higher functional connectivity in MDD patients than in healthy controls. In addition, these networks had higher functional connectivity to the bilateral dorsal medial PFC (an area termed the dorsal nexus) in MDD patients than healthy controls, indicating that the dorsal nexus might explain the compromised concurrent and synergistic behaviors in MDD patients, like rumination and emotional and vegetative dysregulation. Intriguingly, it revealed that the PFC, ACC, and precuneus regions had significantly increased connectivity to the dorsal nexus in MDD patients versus controls (Fig. 3) . Besides the above networks, other important functional connections exist. To explore the pattern of inter-hemispheric functional connectivity in MDD, Lai et al. [77] carried out an investigation in first-episode, medication-naive patients with MDD using resting-state fMRI. They reported that patients presented lower inter-hemispheric connectivity in the anterior sub-network of the DMN (bilateral medial frontal cortex and ACC) and the cerebellar posterior lobe than healthy controls, and demonstrated that the strength of inter-hemispheric connectivity was inversely correlated with depression severity. This study indicated that the cerebellum might play a role in the DMN alterations, and this was further confirmed by a later investigation by Guo et al. [78] .
Hence, it is supposed that MDD is a disorder with dysfunctional neural networks in numerous areas rather than a disease of a single impaired region. Furthermore, the aberrant networks are capable of explaining at least part of the clinical symptoms. Interestingly, networks may show abnormal functional connectivity to the same brain nodes, which further adds our understanding of the concomitant symptoms of MDD patients. Meanwhile, altered functional connectivity values detected by resting-state fMRI have been used to evaluate the therapeutic effect of a diversity of treatments on MDD, such as specific pharmacological treatments, psychological treatment, transcranial magnetic stimulation, and electroconvulsive shock therapy [79] [80] [81] [82] [83] [84] [85] [86] . To date, pharmacotherapy is still the dominant method for patients with MDD. Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is one of the most common drugs for the treatment of MDD patients. One investigation explored the treatment effect of escitalopram in MDD using resting-state fMRI [87] . It presented a group-by-time interaction on functional connectivity strength (FCS) in the bilateral dorsomedial PFC and bilateral hippocampus, and that hyperconnectivity of the bilateral dorsomedial PFC occurred in MDD patients at baseline and subsequently decreased after treatment; on the contrary, the hypoconnectivity of the bilateral hippocampus at baseline in MDD patients subsequently increased after treatment. Moreover, FCS reduction in the dorsomedial PFC was significantly associated with symptom improvement. However, since the treatment outcomes of the SSRI class of antidepressants cannot be extrapolated to norepinephrine reuptake inhibitors [88] [89] [90] [91] , another study focused on the treatment effect of duloxetine-a dual serotonin-norepinephrine reuptake inhibitor-in MDD using MRI [92] . This study showed a group-by-time interaction in the anterior DMN in which MDD patients presented increased functional connectivity with treatment, and that reduced baseline resting-state connectivity in the orbitofrontal component of the anterior DMN is a predictor of greater clinical response.
Taken together, these findings suggest that antidepressants can modulate the disrupted intrinsic network connectivity in MDD patients, thus significantly adding to our understanding of the antidepressant effect at the circuit level and revealing feasible imaging-based biomarkers for the assessment of treatments for MDD. Hence, MRI has potential for aiding in predicting therapeutic effects and exploring prognostic biomarkers to accelerate the progress of treatment for MDD patients.
PET and SPECT
Radionuclide imaging approaches, including SPECT and PET, are molecular imaging modalities that utilize radiolabeled molecules to image the molecular interactions of biological processes in vivo [93] . They have the advantages of high sensitivity and specificity to molecular targets in living subjects [94] , and thus are capable of providing insight into molecular events in vivo, such as blood flow, glucose and oxygen metabolism [95] , and neurotransmitters [96] . Compared with SPECT, PET has a higher sensitivity and relatively faster acquisition of dynamic data, along with the potential to quantify observations.
PET Imaging of Brain Metabolism
Using 18 F-fluoradeoxyglucose ( 18 F-FDG) PET, emerging evidence has shown that MDD patients undergo metabolic changes in the brain during the clinical course and therapeutic process. A recent voxel-based meta-analysis of neuroimaging studies using 18 F-FDG PET compared the cerebral metabolism in MDD patients with healthy controls [97] . The results showed that MDD patients had significantly lower regional cerebral glucose metabolism in the right caudate and cingulate cortex, left lentiform nucleus, putamen, and extra-nuclear (BA 13), and bilateral insula, whereas higher metabolism was detected in the right thalamus, pulvinar, declive of the posterior lobe, and left culmen of the vermis. It has been suggested that these dysfunctional regions might be associated with the pathophysiology of MDD. Moreover, the decreased metabolism in the basal ganglia, limbic system, and insula might be compensated by increased metabolism in the thalamus and cerebellum, in line with the hypothesis proposed in a previous study [98] . However, it is notable that the metabolic alterations in these regions have been reported in other mental illnesses such as schizophrenia [99] , autism [100] , and bipolar disorder [101] . Therefore, further studies are required to investigate the specific dysfunctional regions involved in MDD.
In addition, several studies have focused on discovering the neural predictors of various therapies for MDD with 18 F-FDG PET imaging [102, 103] . Recently, Roffman et al. [102] investigated the neural correlates of short-term psychodynamic psychotherapy in MDD for the first time using this approach. They reported that the pretreatment glucose metabolism in the right posterior insula was markedly and positively correlated with depression severity (Fig. 4a) . Moreover, among patients who completed treatment, a reduced depression score was associated with a pre-to post-treatment reduction in glucose metabolism in the right insula, which in turn was associated with a higher insight rating. These results indicated that the insula, a region paramount in regulating self-monitoring, is prominently implicated in the metabolic process underlying MDD. On the other hand, the pretreatment metabolism in the right precuneus was significantly higher in completers versus non-completers (Fig. 4b ) and positively associated with psychological mindedness (Fig. 4c) , suggesting that precuneus metabolism can be used to predict the therapeutic response with high sensitivity. Hence, all these findings showed that pretreatment glucose metabolism in specific regions such as the insula and precuneus may be of great value in predicting the response to diverse therapeutic methods.
PET and SPECT Imaging of Neurotransmitters
Emerging evidence has shown that the serotonergic system is involved in MDD [104, 105] , mainly based on the control groups for mean resting-state connectivity between the dorsal nexus and the combined regions in dorsal lateral prefrontal cortex, precuneus, and subgenual anterior cingulate cortex (P \ 0.01) [71] . (reprint permission was obtained from both the publisher and the corresponding author) antidepressant effect of SSRIs. Also, most antidepressant medications either directly or indirectly elevate serotonin (5-HT) transmission [106] .
Among the various classes of 5-HT receptors, the 5-HT1A receptor is most common in the brain and was the first to be successfully cloned.
11 C-WAY-100635 is an antagonist radioligand that binds equally to low-and highaffinity 5-HT1A receptors [107] . Using 11 C-WAY-100635 PET, Miller et al. [108] investigated changes in 5-HT1A receptor binding, as well as its association with the standardized treatment effect of escitalopram in MDD patients. The authors demonstrated higher 5-HT1A receptor binding in patients with MDD than controls in various regions such as the ACC, amygdala, dorsolateral PFC, and hippocampus, Fig. 4 Resting 18 F-FDG PET imaging in MDD patients with psychodynamic psychotherapy. a A significant positive correlation between pretreatment HDRS and regional cerebral glucose metabolism was identified in three clusters in and adjacent to the right posterior insula (yellow; P \ 0.05, corrected for whole-brain volume). b Pretreatment regional cerebral glucose metabolism in the right precuneus was significantly higher in completers compared with non-completers (yellow; P \ 0.05, corrected for wholebrain volume). c In all patients, pretreatment glucose metabolism in the right precuneus significantly and positively correlated with psychological mindedness (q = 0.70; P = 0.002) [102] . (reprint permission was obtained from both the publisher and the corresponding author) consistent with previous studies in humans [109, 110] and animals [111, 112] . In addition, remitters to escitalopram had higher baseline 5-HT1A receptor binding in the raphe nuclei than non-remitters. The 5-HT1A receptor is an autoinhibitory autoreceptor located somatodendritically on serotoninergic neurons in the raphe nuclei, as well as on target neurons throughout most brain regions. Thus, these findings suggest that higher 5-HT1A receptor levels in the raphe nuclei lead to lower basal firing rates of serotonergic neurons, and thus lower 5-HT release. After several weeks of SSRI treatment, these raphe autoreceptors become desensitized, resulting in a progressive increase in the firing rates of serotonergic neurons and then increased 5-HT release. The increased 5-HT release united with the elevated serotonergic neurotransmission due to SSRIs demonstrates remission. Nevertheless, others have assumed that SSRIs cause downregulation, rather than desensitization, of the 5-HT1A receptor [107] . Thus, to differentiate desensitization from downregulation, novel PET agonist radioligands that specifically bind to high-affinity 5-HT1A receptors are required. The increase in 5-HT1A receptors in MDD patients has been supported by Lemonde et al. [113] who explored the C(-1019)G 5-HT1A promoter polymorphism in patients with MDD. They reported that the G allele was twofold enriched in depressed patients versus controls and fourfold enriched in suicide completers of whom 52% met the criteria for MDD. This was confirmed in later investigations [110, 114] . The higher-expressing G allele is considered to contribute to the overexpression of autoinhibitory somatodendritic 5-HT1A receptors, resulting in reduced serotonergic neurotransmission.
The serotonin transporter (SERT), located on serotonergic neurons mainly in the dorsal raphe nuclei, is responsible for the modulation of released 5-HT via its reuptake from the extracellular space into presynaptic neurons [115] . Altered SERT has been reported in MDD patients [116] [117] [118] , and has been considered to be involved in the pathophysiology of depression [119] and suicide [115] . Recently, a study by Yeh et al. [120] 18 F]-ADAM is a highly-selective radiotracer for assessing SERT availability [121] . The authors demonstrated that SERT availability in the midbrain, thalamus, and striatum was notably lower in the MDD group, and especially in the depressed suicidal group, than in the control group and assumed that these regions might be involved in the neuropathology of depression and subsequent suicidal behaviors in MDD patients. In addition, midbrain SERT availability was inversely correlated with depression severity on HDRS in the MDD group (Fig. 5) , indicating that more severe symptoms of depression are associated with lower SERT availability. These findings are similar but not identical to previous results [116] [117] [118] 122] , probably due to heterogeneous demographic and clinical characteristics, different radioligands, and methodological differences. More importantly, they also reported that the depressed suicidal group had a higher PFC/midbrain SERT binding ratio than both the depressed non-suicidal and control groups (Fig. 6) . These results suggest that an incongruent reduction of PFC SERT binding in the midbrain might distinguish depressed suicide-attempters from non-attempters among MDD patients and might be related to the pathophysiology of suicide behaviors. Taken together, these investigations elucidated that MDD is associated with abnormalities of the serotonergic system, and emphasized the vital role of the striatum and cortico-basal ganglia pathway in the neuropathology of affective disorders and subsequent suicide behaviors in patients with MDD [123] .
On the other hand, genetic heritability is thought to play a paramount role in the occurrence of MDD, so a relevant family history is a potential risk factor for MDD. To explore whether differences in SERT availability exist between healthy individuals with and without familial risk, Hsieh et al. [124] initiated an investigation using 123 I-2-((2-((dimethylamino) methyl) phenyl)thio)-5-iodophenylamine SPECT. They found that SERT availability in the midbrain was evidently lower in individuals with a first-degree family history of MDD than in healthy controls and hypothesized that midbrain SERT availability could be a promising marker for vulnerability to MDD. Whether the Fig. 5 Inverse correlation between HDRS score and midbrain SERT BP ND . It manifested an inverse correlation between HDRS and midbrain SERT BP ND . SERT, serotonin transporter; BP ND , binding potential of non-displaceable region [120] . (reprint permission was obtained from both the publisher and the corresponding author) midbrain SERT availability is an endophenotype for MDD, however, remains to be further elucidated.
Based on these findings, it appears that an impaired serotonergic system is critically involved in the onset and progression of MDD. However, similar changes in the serotonergic system have also been reported in other neuropsychiatric disorders, such as schizophrenia [125] . Thus, the specificity of the changes remain an issue. In addition, besides involvement of the serotonergic system, abnormal neurotrophin signaling [4] , aberrant expression of inflammatory cytokines [126, 127] , and the dopaminergic system [128] [129] [130] are thought to contribute to the genesis of depression as well. Therefore, the occurrence and development of the disorder is a complex process involving multiple mechanisms. It is imperative to understand the specific mechanisms underlying MDD in order to precisely diagnose and develop targeted and effective treatment approaches.
Conclusions and Future Perspectives
Emerging evidence has revealed that brain structure and activity are significantly altered in MDD, particularly in regions involved in affective and behavioral control. Furthermore, monoamine-deficiency and abnormal networks may underlie MDD. Interestingly, there seems to be a potential association between a dysfunctional serotonergic system and an abnormal DMN. These two major systems may play reciprocal and mutual roles in the cognitive control of affective state and dysfunctions in both may underlie the onset and progression of MDD. However, the mechanisms by which the serotonergic system is related to the DMN, or to other structural and functional network changes, need further clarification. In addition, more research is needed, particularly on exploring how potential imaging biomarkers are associated with behavioral and genetic variations, as well as with therapeutic effects. Fig. 6 The SERT BP ND ratio between PFC and midbrain in depressed suicide, depressed non-suicide patients, and healthy controls. The ratio was significantly higher in the depressed suicide group than in both the depressed non-suicide patients and healthy controls (P \ 0.01). Bars represent mean values. SERT, serotonin transporter; BP ND , binding potential of non-displaceable region; PFC, prefrontal cortex [120] . (reprint permission was obtained from both the publisher and the corresponding author)
